Financial Performance & Growth - IMAX reported a 40% growth in global box office market share from 2018 through 1Q25[11] - The company's 1Q25 Total Adjusted EBITDA margin was 43%[11], exceeding the FY25 guidance of 40%+[96] - IMAX projects over $12 billion in IMAX Box Office revenue for 2025[36] - The company has repurchased 19% of shares outstanding since 2020[11, 124] Network Expansion & Backlog - IMAX's global network scale includes 1,738 systems[11] across 89 countries and territories[11, 38] - The company has a contracted IMAX system backlog of 516 systems[11, 42] - International markets (excluding China) have seen over 27% network growth since pre-pandemic (year-end 2019 to March 31, 2025)[14] Content & Strategy - IMAX is increasing its connection with studios and filmmakers, expecting a record 11 Filmed For IMAX (FFI) Hollywood titles in 2025[11] - The company expects over 60 local language titles in 2025, demonstrating a 27% CAGR from 2019-2024[86, 87] - IMAX is partnering with streaming platforms to eventize and launch content[75] Financial Position - As of March 31, 2025, IMAX has $4015 million in total liquidity[117] - The company's net debt to TTM Total Adjusted EBITDA is 128x[119]

Contract Status Overview - The report provides an overview of Seadrill Limited's fleet contract status as of May 12, 2025 [1] - The fleet includes drillships, benign semi-submersibles, and harsh environment rigs [9, 10] - The report contains forward-looking statements subject to risks and uncertainties [2, 3] Drillship and Semi-Submersible Contracts - West Auriga has a contract with Petrobras in Brazil, with a total contract value at signing of approximately $577 million, including mobilization and additional services [9] - West Carina is contracted with Petrobras in Brazil at a dayrate of $252,600 [9] - West Jupiter has a contract with Petrobras in Brazil, with a total contract value at signing of approximately $525 million, including mobilization and additional services [9] - West Polaris has a contract with Petrobras in Brazil, with a total contract value at signing of approximately $518 million, including mobilization and additional services [9] - West Tellus has a contract with Petrobras in Brazil, with a total contract value at signing of approximately $539 million, including mobilization and additional services [10] - West Neptune has a contract with LLOG in the U.S Gulf, with a total contract value of approximately $86 million, excluding additional services, for an approximate 180-day duration [9] - West Gemini is contracted with TotalEnergies in Angola at a dayrate of $404,800 [9] Harsh Environment Rigs - West Elara is contracted with ConocoPhillips in Norway until March 2028 at a market-indexed rate [10]

MIND Technology, Inc. (NASDAQ: MIND) iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025 June 24-25, 2025 Forward Looking Statement Certain statement and information in this presentation may constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. The words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," or other simila ...

MIND Technology, Inc. Company Overview June 2025 (NASDAQ: MIND) Forward Looking Statement Certain statement and information in this presentation may constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. The words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," or other similar expressions are intended to identify forward- looking s ...

Forward-Looking Statements - The document contains forward-looking statements based on expectations and assumptions that may not be accurate [3] - These statements are subject to risks, uncertainties, and changes in circumstances that are difficult to predict [3] - The company assumes no obligation to update or revise any forward-looking statement [4] Risk Factors - General economic and industry conditions, including regulatory changes, can impact results [3] - Reliance on commercial airline customers poses a risk [3] - The health of the aircraft production system, production quality issues, and the ability to develop and certify new aircraft are critical [3] - Changing government budget levels and acquisition priorities can cause delays [3] - Dependence on subcontractors and suppliers, as well as the availability of skilled labor and raw materials, is a factor [3] - The pending acquisition of Spirit AeroSystems Holdings, Inc, including the satisfaction of closing conditions, is a risk [3]

Financial Performance - GenScript Life Science revenue increased by 26.4% year-over-year[20] - Biologics CDMO revenue increased by 33.6% year-over-year, achieving historical breakeven financial goal[20] - Cell Therapy revenue increased by 101.5% year-over-year, with backlog up 108.4% year-over-year[21] - In FY21, external revenue reached $424.7 million, a 30.8% year-over-year increase[23] - Adjusted net loss of Cell Therapy was $(354.6) million in 2021 compared to $(213.3) million in 2020[23] - Adjusted net profit of Non-Cell Therapy was $50.2 million in 2021, an 18.1% year-over-year increase[23] Investments - R&D expenses for Non-Cell Therapy were $36.3 million and for Cell Therapy were $49.9 million in 2021[25], representing a 36.1% year-over-year increase in total R&D investment[24] - Capital expenditure for Cell Therapy was $47.1 million, for Biologics CDMO was $34.5 million, and for Life Science & Other was $55.8 million in 2021[28] Business Segments - Legend Biotech, a cell therapy company, received an upfront payment of $350 million and $300 million in milestone payments from Janssen[61]

Company Overview - Antengene is focused on bringing transformative medicines to patients globally, with commercialization in 6 APAC markets and 9 clinical-stage assets[12, 13] - The company raised US$21 million in Series A, US$120 million in Series B, US$97 million in Series C, and US$367 million in its Hong Kong IPO[21] - As of June 30, 2023, Antengene had RMB 1,322 million in cash and bank balances[21, 225] Pipeline Highlights - For CPI-naïve relapsed/metastatic cervical cancer, ATG-008 (Onatasertib) showed an ORR of 53.3% (16/30) and mPFS of 8.41 months[15] - In CPI-treated relapsed/metastatic cervical cancer, ATG-008 (Onatasertib) showed an ORR of 29.4% (5/17)[15] - In treatment-naïve myelofibrosis patients, Selinexor 60 mg + Ruxolitinib achieved SVR35 of 83.3% (10/12) at week 12 and 91.7% (11/12) at week 24 in efficacy evaluable patients[30] - In TP53 Wild-type Endometrial Cancer Patients, Selinexor monotherapy showed mPFS of 27.4 months compared to 5.2 months for placebo, with HR: 0.42[32] Commercial Performance & Partnerships - XPOVIO® achieved RMB 72.0 million in revenue in 2023 1H, a 33.5% increase compared to RMB 54.0 million in 2022 1H[15] - Antengene entered into a commercialization partnership with Hansoh Pharma in the Mainland of China on August 11th[15] - XPOVIO® has covered 130 DTP pharmacies across the Mainland of China and attained 46 urban-customized commercial health insurance listings (Huiminbao) covering over 55 million people[202] - From commercial launch in May 2022 to June 30th, 2023, XPOVIO® accumulated revenue of RMB 222.1 Million[202]

Antengene Pipeline Overview - Antengene is developing a diverse pipeline of oncology and autoimmune programs, including T cell engagers and other novel therapies[9, 10] - The company has partnerships and clinical collaborations to advance its programs[10] - Antengene has USD 125 million in cash and bank balances to advance pipeline development and strategic initiatives over the next 3 years[11] ATG-022 (Claudin 18.2 ADC) - ATG-022 demonstrates efficacy across all CLDN18.2 expression levels in gastric cancer, including low and ultra-low expressors[15, 23, 29] - In CLDN18.2 moderate to high expressing GC (IHC 2+ > 20%), ATG-022 showed an ORR of 40% (12/30) and a DCR of 90% (27/30)[10, 31] - In CLDN18.2 low and ultra-low expressing GC (IHC 2+ ≤ 20%), ATG-022 showed an ORR of 30% (3/10) and a DCR of 50% (5/10)[10, 31] - One patient with complete response (CR) has demonstrated durable CR for over 21 months[32] ATG-037 (CD73 Inhibitor) - The immuno-oncology (IO) market is estimated to be over USD 140 billion in 2028, including IO-resistant tumors[44] - In CPI-resistant melanoma, ATG-037 in combination with pembrolizumab showed an ORR of 36.4% (4/11) and a DCR of 100% (11/11)[10] - In CPI-resistant NSCLC, ATG-037 in combination with pembrolizumab showed an ORR of 22.2% (2/9) and a DCR of 67% (6/9)[10] AnTenGager T Cell Engager (TCE) Platform - AnTenGager is a novel second-generation "2+1" TCE platform with steric hindrance-masking technology[65] - ATG-201 (CD19 x CD3) is a TCE being developed for B cell-related autoimmune diseases, with IND targeting 2025 H2[10, 83]

Investor Update MAY 2023 | NASDAQ: IREN Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Iris Energy's future financial or operating performance. For example, forward-looking statements include but are not limited to the Company's business strategy, expected operational and financial results and expected increase in power cap ...

Forward Looking Statements W e intend t o b e covered by, and w e claim the protection of, the safe ‐ harbor provisions for forward ‐ looking statements within the meaning o f the Private Securities Litigation Reform Act o f 1995. You can identify these statements b y forward ‐ looking words such a s "estimate," "may," "could," "will," "believe," "expect," "would," "consider," "should," "anticipate," "project," "plan," "intend," "guidance," "target," o r similar words. I n addition, statements contained wit ...